NO20014845L - Use of arylalkanoylpyridazines - Google Patents

Use of arylalkanoylpyridazines

Info

Publication number
NO20014845L
NO20014845L NO20014845A NO20014845A NO20014845L NO 20014845 L NO20014845 L NO 20014845L NO 20014845 A NO20014845 A NO 20014845A NO 20014845 A NO20014845 A NO 20014845A NO 20014845 L NO20014845 L NO 20014845L
Authority
NO
Norway
Prior art keywords
arylalkanoylpyridazines
osteoporosis
atherosclerosis
tumors
aids
Prior art date
Application number
NO20014845A
Other languages
Norwegian (no)
Other versions
NO20014845D0 (en
Inventor
Jonas Rochus
Michael Wolf
Norbert Beier
Franz-Werner Kluxen
Claus Fittschen
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20014845D0 publication Critical patent/NO20014845D0/en
Publication of NO20014845L publication Critical patent/NO20014845L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Oppfinnelsen vedrører anvendelse av forbindelser med formel (I) d) NH-CO-B hvor R1, R2, Q og B har betydningene an- gitt i krav l, og/eller deres fysiologisk forenlige salter, til fremstilling av et medikament for behandling av osteoporose, tumorer, aterosklerose, reumatoid artritt, multippel sklerose, diabetes mellitus, ulcerøs kolitt og AIDS.The invention relates to the use of compounds of formula (I) d) NH-CO-B wherein R osteoporosis, tumors, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, ulcerative colitis and AIDS.

NO20014845A 1999-04-06 2001-10-05 Use of arylalkanoylpyridazines NO20014845L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19915364A DE19915364A1 (en) 1999-04-06 1999-04-06 Use of arylalkanoylpyridazines
PCT/EP2000/002280 WO2000059484A2 (en) 1999-04-06 2000-03-15 Use of arylalkanoylpyridazines

Publications (2)

Publication Number Publication Date
NO20014845D0 NO20014845D0 (en) 2001-10-05
NO20014845L true NO20014845L (en) 2001-10-05

Family

ID=7903583

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014845A NO20014845L (en) 1999-04-06 2001-10-05 Use of arylalkanoylpyridazines

Country Status (18)

Country Link
EP (1) EP1143944A3 (en)
JP (1) JP2002541095A (en)
KR (1) KR20020000550A (en)
CN (1) CN1355702A (en)
AR (1) AR023261A1 (en)
AU (1) AU3811600A (en)
BR (1) BR0009549A (en)
CA (1) CA2367051A1 (en)
CZ (1) CZ20013598A3 (en)
DE (1) DE19915364A1 (en)
HU (1) HUP0200311A3 (en)
ID (1) ID30381A (en)
MX (1) MXPA01010034A (en)
NO (1) NO20014845L (en)
PL (1) PL350963A1 (en)
RU (1) RU2001129703A (en)
WO (1) WO2000059484A2 (en)
ZA (1) ZA200109120B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050096322A1 (en) * 2002-03-01 2005-05-05 Susumu Igarashi Nitrogen-containing heterocyclic compound
DE10224888A1 (en) * 2002-06-05 2003-12-24 Merck Patent Gmbh pyridazine
DE10225574A1 (en) * 2002-06-10 2003-12-18 Merck Patent Gmbh New 1-acyl-3-phenyl-5,6-dihydro-4H-pyridazine derivatives, are phosphodiesterase IV inhibitors useful e.g. for treating asthma, allergy, inflammation, autoimmune diseases or myocardial diseases
US20060173009A1 (en) * 2003-01-07 2006-08-03 Hiroyuki Kanoh Agent inducing increase in bone mass
AR067354A1 (en) 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc USEFUL COMPOUNDS AS INHIBITORS OF RAF QUINASA

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19632549A1 (en) * 1996-08-13 1998-02-19 Merck Patent Gmbh Arylalkanoylpyridazines
DE19826841A1 (en) * 1998-06-16 1999-12-23 Merck Patent Gmbh Arylalkanoylpyridazines
DE19850701A1 (en) * 1998-11-04 2000-05-11 Merck Patent Gmbh Benzoyl pyridazines
DE19915365A1 (en) * 1999-04-06 2000-10-12 Merck Patent Gmbh Tetrahydropyridazine derivatives

Also Published As

Publication number Publication date
ID30381A (en) 2001-11-29
BR0009549A (en) 2002-03-26
NO20014845D0 (en) 2001-10-05
EP1143944A3 (en) 2002-09-11
HUP0200311A2 (en) 2002-11-28
CZ20013598A3 (en) 2002-01-16
JP2002541095A (en) 2002-12-03
ZA200109120B (en) 2003-11-13
MXPA01010034A (en) 2002-04-24
WO2000059484A3 (en) 2001-08-23
CA2367051A1 (en) 2000-10-12
EP1143944A2 (en) 2001-10-17
AR023261A1 (en) 2002-09-04
RU2001129703A (en) 2004-02-20
DE19915364A1 (en) 2000-10-12
KR20020000550A (en) 2002-01-05
PL350963A1 (en) 2003-02-24
AU3811600A (en) 2000-10-23
WO2000059484A2 (en) 2000-10-12
CN1355702A (en) 2002-06-26
HUP0200311A3 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
ATE217865T1 (en) COMPOUNDS FOR INHIBITING PHOSPHODIESRERASE IV
NO20065178L (en) Tienopyridinderivater
NO20060142L (en) Cyclic tertiary amine compound
HK1088013A1 (en) Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs
GB9903670D0 (en) Liquid crystal compounds
NO20076145L (en) Ureadeviates, processes for their preparation and use thereof
TW200613346A (en) Organoantimony, manufacturing method thereof, active free radical polymerization initiator, polymer manufacture method using the same, and polymer
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
CA2585802A1 (en) Industrial process for the preparation of 17-hydroxy-6.beta.,7.beta.;15.beta.,16.beta.-bismethylene-3-oxo-17.alpha.pregn-4-ene-21-carboxylic acid.gamma.-lactone and key-intermediates for this process
DE50209545D1 (en) LIQUID CRYSTALLINE MEDIUM
ES2081636T3 (en) PREPARATION OF SUBSTITUTED PIPERIDINES.
MXPA03009602A (en) Nociceptin analogs.
CA2037975A1 (en) 5-hydroxy-2,3-dihydrobenzofuran analogs as leukotriene biosynthesis inhibitors
NO20014845L (en) Use of arylalkanoylpyridazines
NO20060258L (en) Nematicidal thiazoline-containing fluorobutenes
WO2002079753A3 (en) 2-aminobenzoxazole derivatives and combinatorial libraries thereof
GB0327323D0 (en) Novel pharmaceuticals
NO20052197L (en) Process for the preparation of pyrazole
DK1598358T3 (en) Compounds containing 3,4-methylenedioxythiophene units
WO2000043375A3 (en) Substituted aryl heterocyclic compounds
NO20020886L (en) Novel integrin <alfa> v <beta> 3 inhibitors
TW200712182A (en) Ferroelectric liquid crystal compound
TW200712181A (en) Antiferroelectric liquid crystal compound
CA2394611A1 (en) Process for the preparation of 1,3-disubstituted 2-nitroguanidines
NO20013681L (en) Acetylenic heteroarylsulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application